At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of ISB 830 in Adult Subjects With Moderate to Severe Atopic Dermatitis.
In Brief
A Phase 2 clinical trial evaluating ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, and 4 other interventions for Moderate to Severe Atopic Dermatitis. Completed, enrolled 462 participants across 83 sites in 5 countries.
Detailed Summary
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis. The study will be conducted in 2 Parts, with dosing Groups 1-4 comprising Part 1, and dosing Groups 5-6 comprising Part 2. All subjects will receive open-label ISB 830 after a 16 week blinded treatment period.
Study Details
Timeline
Interventions
Subcutaneous injection (SC) every 2 weeks
Subcutaneous injection (SC) every 2 weeks
Subcutaneous injection (SC) every 2 weeks
Subcutaneous injection (SC) every 2 weeks
Subcutaneous injection (SC) every 2 weeks
Subcutaneous injection (SC) every 2 weeks